Business Context and Reporting Period
This Form 8-K Current Report is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on January 6, 2014, regarding events occurring on January 2, 2014. The filing details the entry into a material definitive agreement for a private placement offering of securities.
Key Financial Metrics
- Gross Proceeds: $20,000,000
- Net Proceeds (Estimated): $18,700,000
- Units Sold: 6,872,859
- Price Per Unit: $2.91
- Placement Agent Fee: $1,200,000 (6% of gross proceeds)
- Reimbursable Expenses: $15,000
- Securities Issued: 6,872,859 shares of common stock and 3,436,435 warrants.
Material Changes and Transaction Details
The Company entered into an engagement agreement with T.R. Winston & Company, LLC as the Placement Agent. Simultaneously, the Company executed securities purchase agreements with institutional and accredited investors. Each unit consists of one share of common stock and a warrant to purchase 0.5 share of common stock at an exercise price of $3.64. The warrants are exercisable immediately and have a five-year term. The transaction is expected to close on or about January 8, 2014.
Outlook, Risks, and Management Commentary
The offering is registered under a Form S-3 Registration Statement declared effective on September 13, 2013. The filing includes a press release dated January 3, 2014. The filing text does not provide specific forward-looking guidance, risk factors, or management commentary beyond the terms of the transaction and the anticipated closing date. The warrants do not contain price protection provisions regarding subsequent securities issuances.
Investor Verification Checklist
- Verify the actual closing date of the offering (anticipated January 8, 2014).
- Confirm the final net proceeds after all transaction costs are deducted.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.01) for specific covenants or restrictions.
- Check the press release (Exhibit 99.1) for additional context on the use of proceeds.
- Monitor the Company's capital structure for dilution resulting from the issuance of 6.87 million shares and 3.44 million warrants.